Treatment of atopic dermatitis with tradipitant
AssigneeVanda Pharmaceuticals Inc.
InventorsMihael H. Polymeropoulos, Gunther Birznieks, Christos Polymeropoulos
Life of this patent
Estimating the term…
Abstract
The disclosure relates generally to improvements in the treatment of pruritus, atopic dermatitis (AD), and associated symptoms with tradipitant. More particularly, it relates to a method for increasing the likelihood of achieving optimal therapeutic response in the treatment of an AD patient, where the AD patient is one for whom a potential therapy of choice may include the administration of an amount of an NK-1 antagonist, e.g. tradipitant effective to treat the patient's AD.
Claims14
A method for increasing the probability of achieving an optimal therapeutic response in the treatment of an atopic dermatitis patient for whom administering an amount of tradipitant effective to treat atopic dermatitis might be the therapy of choice, comprising:
- examining said patient in a manner sufficient to assess one or both of said patient's Investigator's Global Assessment (IGA) and body surface area (BSA) scores;
- and
- if said patient's IGA score is 2 or less or if said patient's BSA score is 10% or less or if said patient's IGA and BSA scores are respectively 2 or less and 10% or less, prescribing tradipitant for use by said patient in an amount effective to treat said patient's atopic dermatitis, whereupon said amount of tradipitant is administered to said patient;
- and
- if said patient is not prescribed tradipitant based upon said IGA or BSA scores, evaluating whether (1) an alternative medicinal therapy other than tradipitant or (2) the use of tradipitant is the more appropriate medical intervention for treating said patient.
A method for increasing the probability of achieving an optimal therapeutic response in the treatment of an atopic dermatitis patient for whom administering an amount of an NK-1 antagonist effective to treat atopic dermatitis might be the therapy of choice, comprising:
- examining said patient in a manner sufficient to assess one or both of said patient's Investigator's Global Assessment (IGA) and body surface area (BSA) scores;
- and
- if said patient's IGA score is 2 or less or if said patient's BSA score is 10% or less or if said patient's IGA and BSA scores are respectively 2 or less and 10% or less, prescribing the NK-1 antagonist for use by said patient in an amount effective to treat said patient's atopic dermatitis, whereupon said amount of the NK-1 antagonist is administered to said patient;
- and
- if said patient is not prescribed the NK-1 antagonist based upon said IGA or BSA scores, evaluating whether (1) an alternative medicinal therapy other than the NK-1 antagonist or (2) the use of the NK-1 antagonist is the more appropriate medical intervention for treating said patient.
Dependencies are inferred from the claim text.